QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 vyne-therapeutics-q2-eps-013-beats-022-estimate-sales-69000k-miss-150000k-estimate

VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0...

 hc-wainwright--co-downgrades-vyne-therapeutics-to-neutral

HC Wainwright & Co. analyst Joseph Pantginis downgrades VYNE Therapeutics (NASDAQ:VYNE) from Buy to Neutral.

 vyne-therapeutics-announces-phase-2b-trial-with-repibresib-gel-in-nonsegmental-vitiligo-did-not-meet-primary-endpoint-or-key-secondary-endpoint-of-f-vasi50-and-f-vasi75

Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75Nominally Statistically Significant Effec...

 vyne-therapeutics-issues-program-update-for-vyn202-following-clinical-hold-issued-by-fda-in-april-for-phase-1b-clinical-trial-in-treatment-of-moderate-to-severe-plaque-psoriasis

VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focu...

 vyne-therapeutics-q1-eps-020-beats-029-estimate-sales-20200k-beat-5000k-estimate

VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0...

 fda-puts-vyne-therapeutics-early-stage-psoriasis-study-on-hold

VYNE pauses VYN202 psoriasis trial after FDA clinical hold tied to animal toxicity data; separate vitiligo trial remains on tra...

 hc-wainwright--co-maintains-buy-on-vyne-therapeutics-lowers-price-target-to-45

HC Wainwright & Co. analyst Joseph Pantginis maintains VYNE Therapeutics (NASDAQ:VYNE) with a Buy and lowers the price t...

 fda-places-clinical-hold-on-vyne-therapeutics-phase-1b-study-for-vyn202-following-safety-concerns

BRIDGEWATER, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company&...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION